Jin Xing Qi
Chairman bij HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD
Vermogen: 1 642 M $ op 31-03-2024
Profiel
Jin Xing Qi richtte Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. op. Momenteel is hij voorzitter van Hangzhou Binjiang Real Estate Group Co., Ltd. en voorzitter van Hangzhou Pute Equity Investment Co. Ltd. De heer Qi is tevens lid van de raad van bestuur van Hangzhou Binjiang Investment Holding Co., Ltd. en Hangzhou Xincheng Time Square Real Estate Co., Ltd. en vice-voorzitter van Zhejiang Management Research. In het verleden bekleedde de heer Qi de functie van Director bij Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Jin Xing Qi behaalde een MBA aan de Zhejiang University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-09-2023 | 1 505 912 522 ( 55.93% ) | 1 386 M $ | 31-03-2024 | |
| 30-09-2023 | 278 698 950 ( 64.95% ) | 256 M $ | 31-03-2024 |
Actieve functies van Jin Xing Qi
| Bedrijven | Functie | Begin |
|---|---|---|
| HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD | Chairman | 01-01-2003 |
| Zhejiang Management Research | Corporate Officer/Principal | 24-02-2010 |
| Hangzhou Pute Equity Investment Co. Ltd. | Chairman | 07-04-2011 |
Hangzhou Binjiang Investment Holding Co., Ltd.
 Hangzhou Binjiang Investment Holding Co., Ltd. MiscellaneousMiscellaneous Hangzhou Binjiang Investment Holding Co., Ltd. is an investment holding private company based in Hangzhou, China. | Director/Board Member | - |
Hangzhou Xincheng Time Square Real Estate Co., Ltd.
 Hangzhou Xincheng Time Square Real Estate Co., Ltd. Real Estate DevelopmentFinance Part of Hangzhou Binjiang Real Estate Group Co., Ltd., Hangzhou Xincheng Time Square Real Estate Co., Ltd. develops and manages real estate property. The private company is based in Hangzhou, China. | Director/Board Member | - |
Eerdere bekende functies van Jin Xing Qi
| Bedrijven | Functie | Einde |
|---|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Founder | - |
Opleiding van Jin Xing Qi
| Zhejiang University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD | Finance |
| Bedrijven in privébezit | 5 |
|---|---|
Hangzhou Binjiang Investment Holding Co., Ltd.
Hangzhou Binjiang Investment Holding Co., Ltd. MiscellaneousMiscellaneous Hangzhou Binjiang Investment Holding Co., Ltd. is an investment holding private company based in Hangzhou, China. | Miscellaneous |
| Zhejiang Management Research | |
Hangzhou Xincheng Time Square Real Estate Co., Ltd.
Hangzhou Xincheng Time Square Real Estate Co., Ltd. Real Estate DevelopmentFinance Part of Hangzhou Binjiang Real Estate Group Co., Ltd., Hangzhou Xincheng Time Square Real Estate Co., Ltd. develops and manages real estate property. The private company is based in Hangzhou, China. | Finance |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| Hangzhou Pute Equity Investment Co. Ltd. | Finance |
